Profilo
Yona Geffen worked as the Chief Executive Officer at Avraham Pharmaceuticals Ltd.
from 2011 to 2016.
Prior to that, Dr. Geffen held the position of Director-Executive Drug Development at BioLineRx Ltd.
and Vice President-Research & Development at Gamida Cell Ltd.
Dr. Geffen obtained graduate and doctorate degrees from Ben-Gurion University of the Negev.
Precedenti posizioni note di Yona Geffen
| Società | Posizione | Fine |
|---|---|---|
Avraham Pharmaceuticals Ltd.
 Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Amministratore Delegato | 01/12/2016 |
| GAMIDA CELL LTD. | Direttore Tecnico/Scientifico/R&S | - |
| BIOLINERX LTD. | Corporate Officer/Principal | - |
Formazione di Yona Geffen
| Ben-Gurion University of the Negev | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BIOLINERX LTD. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| Aziende private | 1 |
|---|---|
Avraham Pharmaceuticals Ltd.
Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Health Technology |
- Borsa valori
- Insiders
- Yona Geffen
